Intermittent fasting shield against liver inflammation and liver cancer

Fatty liver disease often progresses to chronic liver inflammation and may even lead to liver cancer. Researchers from the German Cancer Research Center (DKFZ) and the University of Tübingen have demonstrated in mice that intermittent fasting on a 5:2 schedule can halt this progression. This fasting regimen reduces the incidence of liver cancer in mice with pre-existing liver inflammation by identifying two proteins in liver cells responsible for the protective effect of fasting. Moreover, an approved drug can partially replicate this effect.

The most prevalent chronic liver condition, non-alcoholic fatty liver disease, poses significant risks, including liver inflammation, cirrhosis, and cancer if left untreated. Intermittent fasting has shown promise in reducing weight and ameliorating metabolic disorders. The study investigates whether this approach can safeguard the liver from fatty degeneration and chronic inflammation, offering potential implications for liver disease prevention and treatment.